Sexcord/ stromal ovarian tumors laboratory findings

Jump to navigation Jump to search

Sexcord/ stromal ovarian tumors Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Sexcord/ Stromal Ovarian Tumors from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X-ray

Echocardiography and Ultrasound

CT scan

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Sexcord/ stromal ovarian tumors laboratory findings On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Sexcord/ stromal ovarian tumors laboratory findings

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Sexcord/ stromal ovarian tumors laboratory findings

CDC on Sexcord/ stromal ovarian tumors laboratory findings

Sexcord/ stromal ovarian tumors laboratory findings in the news

Blogs on Sexcord/ stromal ovarian tumors laboratory findings

Directions to Hospitals Treating Psoriasis

Risk calculators and risk factors for Sexcord/ stromal ovarian tumors laboratory findings

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief:  ; Maneesha Nandimandalam, M.B.B.S.[2]

Overview

Laboratory findings consistent with the diagnosis of sexcord/ stromal ovarian tumors include identifying the presence or absence of tumor markers like AMH: anti-Müllerian hormone; AFP: alpha-fetoprotein; E2: estradiol; hCG: human chorionic gonadotropin; LDH: lactate dehydrogenase; testost: testosterone; andro: androstenedione; DHEA: dehydroepiandrostenedione;

Laboratory Findings

Sex cord-stromal tumors AFP hCG LDH E2 Inhibin Testosterone Androstenedione DHEA AMH
Thecoma-fibroma - - - - - - - - -
Granulosa cell tumors - - - +/- + +/- - - +
Sertoli-Leydig tumors +/- - - +/- +/- +/- +/- +/- -

AMH: anti-Müllerian hormone; AFP: alpha-fetoprotein; E2: estradiol; hCG: human chorionic gonadotropin; LDH: lactate dehydrogenase; testost: testosterone; andro: androstenedione; DHEA: dehydroepiandrostenedione; .

References

  1. Rey RA, Lhommé C, Marcillac I, Lahlou N, Duvillard P, Josso N, Bidart JM (March 1996). "Antimüllerian hormone as a serum marker of granulosa cell tumorsof the ovary: comparative study with serum alpha-inhibin and estradiol". Am. J. Obstet. Gynecol. 174 (3): 958–65. PMID 8633676.
  2. Robertson DM, Cahir N, Burger HG, Mamers P, Groome N (March 1999). "Inhibin forms in serum from postmenopausal women with ovarian cancers". Clin. Endocrinol. (Oxf). 50 (3): 381–6. PMID 10435065.
  3. Robertson DM, Stephenson T, Pruysers E, Burger HG, McCloud P, Tsigos A, Groome N, Mamers P, McNeilage J, Jobling T, Healy D (May 2002). "Inhibins/activins as diagnostic markers for ovarian cancer". Mol. Cell. Endocrinol. 191 (1): 97–103. PMID 12044923.
  4. Markova D, Milchev N, Batashki I, Uchikov A (2008). "[Role of total inhibin in diagnosis and monitoring of ovarian cancer in postmenopausal women]". Akush Ginekol (Sofiia) (in Bulgarian). 47 (1): 16–9. PMID 18642569.
  5. Robertson DM, Stephenson T, Pruysers E, McCloud P, Tsigos A, Groome N, Mamers P, Burger HG (February 2002). "Characterization of inhibin forms and their measurement by an inhibin alpha-subunit ELISA in serum from postmenopausal women with ovarian cancer". J. Clin. Endocrinol. Metab. 87 (2): 816–24. doi:10.1210/jcem.87.2.8198. PMID 11836327.
  6. Kurihara S, Hirakawa T, Amada S, Ariyoshi K, Nakano H (December 2004). "Inhibin-producing ovarian granulosa cell tumor as a cause of secondary amenorrhea: case report and review of the literature". J. Obstet. Gynaecol. Res. 30 (6): 439–43. doi:10.1111/j.1447-0756.2004.00231.x. PMID 15566459.
  7. Ran S, Yu Q, Deng S, Xu L (April 2017). "Luteinizing hormone elevation in ovarian granulosa cell tumor: a case report and review of the literature". J Ovarian Res. 10 (1): 30. doi:10.1186/s13048-017-0327-2. PMC 5404692. PMID 28438188.
  8. Bufa A, Farkas N, Preisz Z, Poór V, Páger C, Szukits S, Farkas B, Gőcze PM (June 2017). "Diagnostic relevance of urinary steroid profiles on ovarian granulosa cell tumors: two case reports". J Med Case Rep. 11 (1): 166. doi:10.1186/s13256-017-1324-1. PMC 5480180. PMID 28637499.

Template:WH Template:WS